BDBM620564 US20230303513, Example 12::US20230303513, Example 13

SMILES CCn1cccc(N2C[C@H]([C@H](NC(=O)NC3CCc4cc(OC)ccc4C3)C2=O)c2ccc(OC)cc2)c1=O

InChI Key InChIKey=QDNUNMYEOPDGFU-UHFFFAOYSA-N

Data  4 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 620564   

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620564(US20230303513, Example 13 | US20230303513, Example...)
Affinity DataEC50:  0.800nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620564(US20230303513, Example 13 | US20230303513, Example...)
Affinity DataEC50:  0.900nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetN-formyl peptide receptor 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620564(US20230303513, Example 13 | US20230303513, Example...)
Affinity DataEC50:  1.30nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent

TargetfMet-Leu-Phe receptor(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM620564(US20230303513, Example 13 | US20230303513, Example...)
Affinity DataEC50:  0nMAssay Description:FPR2 and FPR1 Cyclic Adenosine Monophosphate (cAMP) Assays were used to measure the activity of the compounds in this patent. FPR2 and FPR1 Cyclic Ad...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/6/2023
Entry Details
US Patent